Vancouver, British Columbia – April 1, 2011 – Sirona Biochem Corp. (TSX-V: SBM) (the “Company”), a biotechnology company developing diabetes therapeutics, cosmeceuticals and biological ingredients, announced today that it has received a 2011 TSX Venture 50 Award from the TSX Venture Exchange. Dr. Howard Verrico, Sirona Biochem’s Chief Executive Officer, attended the awards ceremony in Toronto yesterday to accept the award.
Sirona Biochem ranked second in TSX Venture 50’s list of top ten leading technology and life sciences companies. The 2011 TSX Venture 50 recognizes top performing companies that are listed on the TSX Venture Exchange. Companies are chosen based on share price appreciation, trading volume, market capitalization growth and analyst coverage, with equal weighting to each.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, cosmeceuticals and biological ingredients. We are applying a proprietary chemistry technique to improve the pharmaceutical properties of our carbohydrate-based molecules. Our lead product, a sodium glucose transporter (SGLT) inhibitor for Type 2 diabetes, recently achieved positive preclinical results. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Phone: 604.641.4466 x273
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.